alexa The Quest For Cost Effective Treatment In Rheumatoid Arthritis: Are Biosimilars The Right Choice?
ISSN: 1948-593X

Journal of Bioanalysis & Biomedicine
Open Access

Like us on:
OMICS International organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific Societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Open Access Journals gaining more Readers and Citations

700 Journals and 15,000,000 Readers Each Journal is getting 25,000+ Readers

This Readership is 10 times more when compared to other Subscription Journals (Source: Google Analytics)

Share This Page

Additional Info

Loading
Loading Please wait..
 

3rd International Conference and Exhibition on Biowaivers, Biologics & Biosimilars
October 27-29, 2014 Hyderabad International Convention Centre, Hyderabad, India

Phani Kishore Thimmaraju
Posters: J Bioanal Biomed
DOI: 10.4172/1948-593X.S1.014
Abstract
The cost associated with the treatment of rheumatoid arthritis has become increasingly difficult to manage over the recent years. Although the targeted therapies have revolutionized the treatment of several rheumatic diseases, the high cost associated with these therapies has become a burden on payers. With the market exclusivity of major biologics to treat RA is near to expire, the focus has shifted to develop biosimilars with comparable efficacy and safety. Apart from scientific advancement and reverse engineering, increasing demand for cost effective biologics is a determinant factor to develop biosimilars. Increasing penetration and uptake of EPO (Epoetin) biosimilars particularly in EU 5 countries in the last five years suggests their growing popularity. In 2013, the Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion, recommending the granting of a marketing authorisation for Remsima and Inflectra (Infliximab biosimilar). This is a remarkable support from EMA (European Medicines Agency) to the pharmaceutical companies developing monoclonal antibody (mAb) biosimilars for rheumatoid arthritis. Currently, the issues on interchangeability and substitution have become the locus of debate for the approval of biosimilars and needs to be resolved at the earliest. Similar to hormone biosimilars currently marketed worldwide, the biosimilar mABs are also expected to be launched at a price around 25% less than the originator. Addressing the concerns on efficacy and safety issues, the price factor might give biosimilars an added advantage in gaining acceptance from various stakeholders.
Biography
Phani Kishore Thimmaraju is a Consultant at Phamax AG and is associated with competitive intelligence division at Bangalore office. He graduated in pharmaceutical science and holds Master?s diploma in Biotechnology from University of Essex, UK. He has over five years of experience in business intelligence and allied areas. He has conducted several workshops and presented at international conferences. He has published peer reviewed articles and white papers in reputed journals and company website.
image PDF   |   image HTML
 
Peer Reviewed Journals
 
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2017-18
 
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals

Ronald

[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

 
© 2008- 2017 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
adwords